🔎 Trials Near Me

Gara Jalqabaatti › Diffuse Large B-Cell Lymphoma › Distaarikii Koloombiyaa › Washington

Qorannoo klinikaalii Diffuse Large B-Cell Lymphoma Washington, DC keessatti

Qorannoo 12 Diffuse Large B-Cell Lymphoma f Washington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Namoota walitti qabaa jiraSadarkaa 1/2
  • American Oncology Partners of Maryland Pa, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05006716

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Namoota walitti qabaa jiraSadarkaa 2
  • MedStar Georgetown University Hospital, Washington D.C.
  • The Center for Cancer and Blood Disorders, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06500273

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Namoota walitti qabaa jiraSadarkaa 2
  • Walter Reed National Military Medical Center, Bethesda · Miili 7 fagaatti
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06649812

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Namoota walitti qabaa jiraSadarkaa 1/2
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT03223610

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Namoota walitti qabaa jiraSadarkaa 2
  • Georgetown University Medical Center ( Site 0117), Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06890884

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Namoota walitti qabaa jiraSadarkaa 2
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT04002947

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Namoota walitti qabaa jiraSadarkaa 1/2
  • Medstar Georgetown University Hospital, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT05826535

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Namoota walitti qabaa jiraSadarkaa 1
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT05389423

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Namoota walitti qabaa jiraSadarkaa 3
  • MedStar Georgetown University Hospital, Washington D.C.
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT07188558

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Namoota walitti qabaa jiraSadarkaa 1
  • National Institute of Health, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT05131022

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Namoota walitti qabaa jiraSadarkaa 1
  • National Institutes of Health Clinical Center, Bethesda · Miili 7 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Bit-2026 · NCT04830137

Qorannoo Diffuse Large B-Cell Lymphoma magaalota biroo keessatti

Qorannoo biroo Washington keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.